Cyano-Substituted Cyclic Hydrazine for Selective JAK1 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing JAK inhibitors lack selectivity, leading to toxic side effects such as immune-related issues and non-immune complications, particularly pulmonary embolism, due to the inhibition of JAK2.
Innovation Solution
Development of a cyano-substituted cyclic hydrazine derivative with high selectivity for JAK1 and activity, characterized by specific structural components and synthesis methods, including nitrosylation, reduction, ring-closure, and deprotection steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing JAK inhibitors are used to treat inflammatory and autoimmune diseases, then therapeutic effects are achieved, but toxic side effects occur due to lack of selectivity and inhibition of JAK2
Solution Approach 1:
The patent applies local quality by designing a specific molecular structure (Formula I) with particular substituents at defined positions that confers selective binding affinity to JAK1 over JAK2. The structural features including the heterocyclic ring A, specific substituent patterns, and cyano-substituted cyclic hydrazine moiety are optimized to interact preferentially with JAK1's binding pocket, thereby achieving local selectivity that reduces off-target effects on JAK2 and other kinases.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types (R1, R2, R3 definitions), ring structures (ring A options), and positional isomers to optimize the balance between JAK1 inhibition potency and JAK2 selectivity. By adjusting these chemical parameters, the compound achieves high JAK1 selectivity while maintaining therapeutic efficacy, thereby reducing toxic side effects associated with non-selective JAK inhibition.
2Reliability
If JAK2 is inhibited to treat diseases, then certain therapeutic benefits are achieved, but pulmonary embolism and other serious side effects occur
Solution Approach 1:
The patent applies the taking out principle by extracting the JAK2 inhibition function from the therapeutic mechanism while retaining JAK1 inhibition. The designed compound selectively targets JAK1 and minimizes JAK2 inhibition, thereby separating the desired therapeutic effect (mediated by JAK1 inhibition in inflammatory and autoimmune conditions) from the harmful effect (pulmonary embolism risk associated with JAK2 inhibition). This functional extraction allows treatment of inflammatory diseases without the serious side effects linked to JAK2 suppression.
3Adaptability or versatility
If non-selective JAK inhibitors are used, then broad therapeutic coverage is achieved, but immune-related and non-immune side effects increase
Solution Approach 1:
The patent applies segmentation by dividing the JAK kinase family into distinct targets (JAK1, JAK2, JAK3, TYK2) and designing a compound that selectively inhibits only JAK1. This segmentation approach allows precise targeting of the specific kinase isoform responsible for inflammatory and autoimmune pathology while sparing other kinases, thereby maintaining adaptability for treating JAK1-mediated diseases while reducing immune-related side effects caused by broad-spectrum inhibition.
Data Source
AI summary
The present invention provides a cyano-substituted cyclic hydrazine derivative, comprising: a compound represented by the following structural formula or a stereoisomer, a geometric isomer, a tautomer, a racemate, a hydrate, a solvate, a metabolite and a pharmaceutically acceptable salt or a prodrug thereof. The compound is used for prevention, treatment or alleviation of autoimmune diseases or proliferative diseases in patients, and/or for inhibiting or modulating protein kinase activity.